These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25636656)

  • 1. The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.
    Strobl AN; Thompson IM; Vickers AJ; Ankerst DP
    J Urol; 2015 Jul; 194(1):58-64. PubMed ID: 25636656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.
    Parekh DJ; Ankerst DP; Higgins BA; Hernandez J; Canby-Hagino E; Brand T; Troyer DA; Leach RJ; Thompson IM
    Urology; 2006 Dec; 68(6):1152-5. PubMed ID: 17169636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
    Pepe P; Aragona F
    Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Thompson IM; Cronin AM; Roobol MJ; Hugosson J; Stephen Jones J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ
    World J Urol; 2012 Apr; 30(2):181-7. PubMed ID: 22210512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
    Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
    BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
    Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
    J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
    Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
    Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.
    Jalali A; Foley RW; Maweni RM; Murphy K; Lundon DJ; Lynch T; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Durkan GC; Murphy TB; Watson RW
    BMC Med Inform Decis Mak; 2020 Jul; 20(1):148. PubMed ID: 32620120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer risk assessment tools in an unscreened population.
    Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
    World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
    Carbunaru S; Nettey OS; Gogana P; Helenowski IB; Jovanovic B; Ruden M; Hollowell CMP; Sharifi R; Kittles RA; Schaeffer E; Gann P; Murphy AB
    BMC Urol; 2019 Nov; 19(1):121. PubMed ID: 31771578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
    Nguyen CT; Yu C; Moussa A; Kattan MW; Jones JS
    J Urol; 2010 Feb; 183(2):529-33. PubMed ID: 20006887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools.
    Tolksdorf J; Kattan MW; Boorjian SA; Freedland SJ; Saba K; Poyet C; Guerrios L; De Hoedt A; Liss MA; Leach RJ; Hernandez J; Vertosick E; Vickers AJ; Ankerst DP
    BMC Med Res Methodol; 2019 Oct; 19(1):191. PubMed ID: 31615451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.
    Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T
    BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome.
    Vickers AJ; Sjoberg DD; Ankerst DP; Tangen CM; Goodman PJ; Thompson IM
    Cancer; 2013 Aug; 119(16):3007-11. PubMed ID: 23720006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.
    Poyet C; Wettstein MS; Lundon DJ; Bhindi B; Kulkarni GS; Saba K; Sulser T; Vickers AJ; Hermanns T
    J Urol; 2016 Nov; 196(5):1402-1407. PubMed ID: 27188476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
    Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
    BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.
    Wu YS; Zhang N; Liu SH; Xu JF; Tong SJ; Cai YH; Zhang LM; Bai PD; Hu MB; Jiang HW; Na R; Ding Q; Sun YH
    Asian J Androl; 2016; 18(6):925-929. PubMed ID: 27212127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Jones JS; Cronin AM; Roobol MJ; Hugosson J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ; Thompson IM
    World J Urol; 2014 Feb; 32(1):185-91. PubMed ID: 22527674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population].
    Zhu XD; Zheng A; Wang ZQ; Shao Q
    Zhonghua Nan Ke Xue; 2018 Feb; 24(2):142-146. PubMed ID: 30156074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population.
    Foley RW; Lundon DJ; Murphy K; Murphy TB; Galvin DJ; Watson RW
    Ir J Med Sci; 2015 Sep; 184(3):701-6. PubMed ID: 25843017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.